by Eclosion Team | Oct 20, 2020 | Uncategorized
Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), abiopharmaceutical company andleader inNOXtherapies, today announced that its lead drug candidate, setanaxib, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA)for...
by Eclosion Team | Jul 21, 2020 | Uncategorized
Geneva, Switzerland,21July2020 –08:00amCEST –GeNeuro(Euronext Paris: CH0308403085 –GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced...
by Eclosion Team | Jun 25, 2020 | Uncategorized
Geneva, Switzerland, June 25, 2020–7:30 amCEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple sclerosis...
by Eclosion Team | May 5, 2020 | Uncategorized
NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate anti-PD-1 resistance Lyon,...
by Eclosion Team | Apr 21, 2020 | Uncategorized
Geneva, Switzerland, April 21, 2020–7:30am CEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple...